As drug development is extremely expensive, the identification of novel indications for in-market drugs is financially attractive. Multiple algorithms are used to support such drug repurposing, but highly reliable methods combining simulation of intracellular networks and machine learning are currently not available. We developed an algorithm that simulates drug effects on the flow of information through protein-protein interaction networks, and used support vector machine to identify potentially effective drugs in our model disease, psoriasis. Using this method, we screened about 1,500 marketed and investigational substances, identified 51 drugs that were potentially effective, and selected three of them for experimental confirmation. All drugs inhibited tumor necrosis factor alpha-induced nuclear factor kappa B activity in vitro, suggesting they might be effective for treating psoriasis in humans. Additionally, these drugs significantly inhibited imiquimod-induced ear thickening and inflammation in the mouse model of the disease. All results suggest high prediction performance for the algorithm.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836852PMC
http://dx.doi.org/10.1002/cpt.769DOI Listing

Publication Analysis

Top Keywords

drug repurposing
8
flow protein-protein
8
protein-protein interaction
8
interaction networks
8
model disease
8
drugs inhibited
8
drugs
5
drug
4
repurposing simulating
4
simulating flow
4

Similar Publications

Objectives: COVID-19 and systemic sclerosis (SSc) share multiple similarities in their clinical manifestations, alterations in immune response, and therapeutic options. These resemblances have also been identified in other immune-mediated inflammatory diseases where a common genetic component has been found. Thus, we decided to evaluate for the first time this shared genetic architecture with SSc.

View Article and Find Full Text PDF

Antifungal activity of 2-adamantylamine hydrochloride on and .

J Med Microbiol

January 2025

Department of Stem Cell and Regenerative Medicine, Medical Biotechnology, Centre for Interdisciplinary Research, D.Y. Patil Education Society (Deemed to be University), Kolhapur- 416-003, Maharashtra, India.

Increased virulence and drug resistance in species of resulted in reduced disease control and further demand the development of potent antifungal drugs. The repurposing of non-antifungal drugs and combination therapy has become an attractive alternative to counter the emerging drug resistance and toxicity of existing antifungal drugs against and non-albicans species. This study aimed to accelerate antifungal drug development process by drug repurposing approach.

View Article and Find Full Text PDF

Tumour heterogeneity and personalized treatment screening based on single-cell transcriptomics.

Comput Struct Biotechnol J

December 2024

School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong 518107, China.

According to global cancer statistics for the year 2022, based on updated estimates from the International Agency for Research on Cancer, there were approximately 20 million new cases of cancer in 2022 alongside 9.7 million related deaths. Lung, breast, colorectal, gastric, and liver cancers are the most common types of cancer.

View Article and Find Full Text PDF

Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.

Front Oncol

January 2025

Laboratorio de Farmacogenética, UMIEZ, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.

Drug repositioning, the practice of identifying novel applications for existing drugs beyond their originally intended medical indications, stands as a transformative strategy revolutionizing pharmaceutical productivity. In contrast to conventional drug development approaches, this innovative method has proven to be exceptionally effective. This is particularly relevant for cancer therapy, where the demand for groundbreaking treatments continues to grow.

View Article and Find Full Text PDF

Dual modality feature fused neural network integrating binding site information for drug target affinity prediction.

NPJ Digit Med

January 2025

State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China.

Accurately predicting binding affinities between drugs and targets is crucial for drug discovery but remains challenging due to the complexity of modeling interactions between small drug and large targets. This study proposes DMFF-DTA, a dual-modality neural network model integrates sequence and graph structure information from drugs and proteins for drug-target affinity prediction. The model introduces a binding site-focused graph construction approach to extract binding information, enabling more balanced and efficient modeling of drug-target interactions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!